Next Article in Journal
Discovery of Anti-Inflammatory Triterpenoid Glucosides from the Heritiera littoralis Dryand
Previous Article in Journal
Plantago Ovata Husk: An Investigation of Raw Aqueous Extracts. Osmotic, Hydrodynamic and Complex Rheological Characterisation
Previous Article in Special Issue
Synthesis of New Azetidine and Oxetane Amino Acid Derivatives through Aza-Michael Addition of NH-Heterocycles with Methyl 2-(Azetidin- or Oxetan-3-Ylidene)Acetates
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 28
Issue 4
10.3390/molecules28041662
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis of Novel Benzo[b][1,6]naphthyridine Derivatives and Investigation of Their Potential as Scaffolds of MAO Inhibitors

by
Larisa N. Kulikova
1,
Ghulam Reza Raesi
1,
Daria D. Levickaya
1,
Rosa Purgatorio
2,
Gabriella La Spada
2,
Marco Catto
2,
Cosimo D. Altomare
2 and
Leonid G. Voskressensky
1,*
1
Organic Chemistry Department, Peoples’ Friendship University of Russia (RUDN University), Miklukho-Maklaya St. 6., 117198 Moscow, Russia
2
Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, Via E. Orabona 4, 70125 Bari, Italy
*
Author to whom correspondence should be addressed.
Molecules 2023, 28(4), 1662; https://doi.org/10.3390/molecules28041662
Submission received: 27 January 2023 / Revised: 4 February 2023 / Accepted: 7 February 2023 / Published: 9 February 2023
(This article belongs to the Special Issue Recent Advances in Heterocycles Synthesis)
Browse Figures
Review Reports Versions Notes

Abstract

:
In this work, 2-alkyl-10-chloro-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridines were obtained and their reactivity was studied. Novel derivatives of the tricyclic scaffold, including 1-phenylethynyl (5), 1-indol-3-yl (8), and azocino[4,5-b]quinoline (10) derivatives, were synthesized and characterized herein for the first time. Among the newly synthesized derivatives, 5c–h proved to be MAO B inhibitors with potency in the low micromolar range. In particular, the 1-(2-(4-fluorophenyl)ethynyl) analog 5g achieved an IC50 of 1.35 μM, a value close to that of the well-known MAO B inhibitor pargyline.

1. Introduction

Naphthyridines (pyridopyridines) are nitrogen-containing heterocyclic analogs of naphthalene. Naphthyridines are classified into six types, depending on the location of the nitrogen atoms in the benzene rings [1]. Due to the wide range of biological activities shown by its derivatives, the interest toward the 1,6-naphthyridine nucleus has increased over recent years [2,3,4]. Several functionalized naphthyridines and their benzo/heteroannulated analogs show biological activities, with prospective exploitation as antitumor agents [5,6], mGlu5 receptor antagonists [7], tyrosine kinase SYK inhibitors [8], and antiviral agents [9]. Moreover, benzocondensed naphthyridine is the scaffold of the alkaloid aaptamine contained in the Indonesian sponge Aaptos suberitoides [10,11], which is endowed with antibacterial and anticarcinogenic activities [12]. Derivatives of benzo[b][1,6]naphthyridine showed antiproliferative (A) and cytotoxic (B) activities against various types of cancer cells [13,14], as well as PDE5 inhibitory activity (C) (Figure 1) [15].
The interest in this bioactive azaheterocyclic moiety prompted us to further explore its reactivity by synthesizing new original derivatives that could possibly be targeted to the treatment of neurological disorders such as Parkinson’s (PD) and Alzheimer’s (AD) diseases [16,17]. Herein, 2-alkyl-10-chloro-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridines (3) were prepared and used as starting materials to synthesize novel derivatives, e.g., bearing X-substituted phenylethynyl or indolyl groups at C(1). A 6→8 ring expansion reaction was also applied to compounds 3 to obtain azocino[4,5-b]quinoline derivatives.
The biological study combining cheminformatics and biochemical testing focused on AD-related targets. In our ongoing search for biological activities from unconventional chemical scaffolds [18,19], we considered the newly synthesized 1,6-benzonaphthyridine derivatives as worthy of biological investigation. It must be highlighted than piperidine-fused naphthyridine derivatives were previously described by others as dual inhibitors of monoamine oxidase subtypes A and B (MAOs A and B) and of acetyl- and butyrylcholinesterase (AChE, BChE) [20]. This feature is also suggested by the shape similarity of this tricyclic scaffold with that of β-carboline, found in the alkaloid harmine and other compounds displaying inhibitory activity toward MAO subtypes [21]. In this study, relying on chemoinformatic predictions, we prioritized the evaluation of inhibitory activity against MAOs A and B.

2. Results and Discussion

2.1. Chemistry

The synthesis of benzonaphthyridines is mainly based on ring-closing methods, which are used in the synthesis of quinolines. The use of Frindler [22], Pfitzinger [23] and Niementowski [24] reactions, as well as synthesis based on 2-ethynylquinolyl-3-carbaldehydes [25] and aminopyridines [26], makes it possible to obtain derivatives containing functional groups in various positions of the tricyclic system.
Previously, we described conversion of tetrahydrobenzo[b][1,6]naphthyridines, which were obtained by the Pfitzinger reaction, to various derivatives under the action of activated alkynes. The structure of the products directly depended on the nature of the substituent in position 10 and Stevens rearrangement products, ylides, 2-vinylquinolines, and benzopyridonaphthyridines can be formed [27,28,29]. However, the mentioned works were mainly focused on substances with acceptor substituents at position 10 because of their easy synthesis by the Pfitzinger reaction. Thus, it was of interest to perform experiments using substances with electron-donating substituents such as chlorine. N-methyl- and benzyl-10-chloro-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridines 3a–d were synthesized by the Niementowski reaction based on condensation of anthranilic acids 1a–c with the appropriate piperidones 2a,b when heated in a phosphorus oxychloride atmosphere. After alkaline treatment of the reaction mass, compounds 3a–d were obtained in the form of yellow crystals with yields of 68–92% (Scheme 1).
The study of the reactivity of 10-chloro-tetrahydrobenzo[b][1,6]naphthyridines showed that 2-methyl-10-chloro-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine 3c was completely inactive in reactions with activated alkynes. Extended boiling and microwave activation in various solvents did not lead to the formation of products, whereas only the initial compound was released back from the reaction mass. However, the presence of an acceptor substituent at C-8 in compound 3d made it possible to obtain product 4c. The reaction of 2-benzyl-10-chloro-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridines 3a,b with methyl propiolate proceeded at room temperature in methanol under acid catalysis conditions. The N-vinyl derivatives 4a,b were obtained as a result of debenzylation (Scheme 2). We previously described such transformations for N-benzyl-chromenopyridines [30].
We supposed that the functionalization of this system by introducing indole or phenylethynyl fragments onto the tetrahydropyridine ring would significantly expand the potential of tetrahydrobenzo[b][1,6]naphthyridines as biologically active compounds and reveal new ways of further achieving chemical modifications. The introduction of a substituent to the nearest position of the nitrogen atom in the tetrahydropyridine fragment was performed by imine salt formation. Such reactions are well described for tetrahydroisoquinolines [31,32,33,34], but they never have been used in case of tetrahydrobenzonaphthyridines. 1-Phenylethynylated benzonaphthyridines 5a–h were obtained as result of the cross-combination of compounds 3 with phenylacetylene in the presence of CuI and diisopropyldiazodicarboxylate (DIAD) (Scheme 3 and Table 1).
The nucleophilic addition of benzonaphthyridine tertiary nitrogen to DIAD led to the formation of a zwitterion, which then turned into an iminium salt. The target products 5 were obtained after further alkynylation of the salt with copper acetylenide. The isolation of the reaction products was hampered by the presence of substituted hydrazine in the reaction mixture. This compound was obtained from DIAD and crystalized simultaneously with the target compounds, so it was necessary to use column chromatography.
The structure of compound 5a was determined by single crystal X-ray analysis (CCDC 2224256, Figure 2).
The phenylethynyl derivatives of benzo[b][1,6]naphthyridines 5 turned out to be much more reactive towards activated alkynes. The reaction with methyl propiolate in trifluoroethanol and acetonitrile took place at room temperature after 10 min with the formation of complex separable mixtures. After selecting the reaction conditions, we obtained satisfactory results using subzero temperatures and isopropanol as a solvent. As a result of the interaction of compounds 5d,g with methyl propiolate under these conditions, two products were formed: the Stevens rearrangement products 6a,b and 2-vinylquinoline 7. The reaction of compounds 5g and 5d also yielded quinoline 7. Under the same conditions, the interaction of compounds 5c,d,f,g with acetylacetylene led to the formation of products 6c–f, the only products with good yields (Scheme 4 and Table 2).
Similarly, the Stevens rearrangement occurred in the case of 1-phenylethynyl-substituted-β-carbolines reacted with activated alkynes [35].
The formation of products 6 and 7 started with the Michael addition of nitrogen of the tetrahydropyridine fragment to the activated alkyne leading to the formation of the zwitterion A. Then, either a Stevens rearrangement (route a) took place with the formation of compound 6, or further attack on the triple bond of the phenylethynyl fragment yielded adduct C (route b) and then proton migration and Hoffmann elimination completed this cascade of transformations to give minor product 7 (Scheme 5).
Besides phenylethynylation, we introduced an indole fragment at position C1 of benzonaphthyridines 3. At the first stage, iminium salts were obtained by interaction of benzonaphthyridines 3 with DIAD, and these salts reacted with substituted indoles at the second stage. The reaction was carried out in absolute THF and benzonaphthyridines 8 were isolated by column chromatography. The isolation of the products was hampered by the presence of substituted hydrazine as in the case of phenethynylation. Thus, only compound 8a was isolated in its individual form, whereas compounds 8b-d were isolated in mixture with hydrazine 9 (Scheme 6).
The interaction of 1-indol-3-yl derivatives of benzo[b][1,6]naphthyridines 8 with acetylacetylene in isopropanol led to the expansion of the tetrahydropyridine fragment, with the formation of azocine 10 (Scheme 7).
Here, we describe the first example of the formation of tetrahydroazocino[4,5-b]quinolines; however, such transformations have been studied for other heterocyclic systems annulated with the tetrahydropyridine fragment and the mechanism of azocine fragment formation has been presented [36,37,38,39,40,41].

2.2. Evaluation of Monoamine Oxidase (MAO) Inhibition

Taking advantage of PLATO, a free online platform for structure-based target prediction [42] that relies on a multi-fingerprint similarity search algorithm [43,44], we submitted derivatives 3a–d, 5a–h, 8a–b, and 10a–c for bioactivity prediction. Interestingly, MAOs were found among the targets predicted with higher probability along with binding affinities for dopamine and opioid receptor subtypes only for the N(2)-methyl analogues 5c–h bearing phenylethynyl groups at C1. In contrast, N(2)-benzyl analogs 5a–b and compounds 3, 8, and 10 were unpredicted as MAO ligands.
Compounds 5c–h were then tested on human (h) recombinant MAO A and B using previously reported assays [16,17]. The MAO-B-selective inhibitor, pargyline, was used as the positive control. Each compound was first tested at a concentration of 10 μM and then lower scalar concentrations were tested when >60% inhibition was achieved at 10 μM. The IC50 values were calculated from the best-fitting inhibition–concentration curves. The MAO A and B inhibition data are summarized in Table 3.
All of the tested compounds showed a certain selectivity toward MAO B, with most of them achieving IC50 values in the low micromolar range. The 4-F derivative 5g showed a noteworthy IC50 (1.35 μM), a value that is even lower than that of the reference pargyline. The absence of chemical groups able to create covalent bonds, such as the propargylamine fragment in pargyline, suggested a tight, yet reversible, interaction at the binding site of the enzyme for 5g. Compounds 5c–h were also assayed as inhibitors of human cholinesterases [45], but they proved to be inactive as AChE inhibitors and scarcely active toward BChE at 10 μM. Meanwhile, the 4-Cl derivative 5h displayed less than 44% antiaggregating activity against amyloidogenic Aβ(1-40) peptide at 100 μM.

3. Materials and Methods

3.1. Chemistry

Materials and general procedures. All reagents and solvents were purchased from Merck (Darmstadt, Germany), J.T. Baker (Phillipsburg, NJ, USA), or Sigma-Aldrich Chemical Co. (St. Louis, MO, USA) and, unless specified, used without further purification. The melting points (m.p.) of all of the compounds were determined using a SMELTING POINT 10 apparatus in open capillaries (Bibby Sterilin Ltd., Stone, UK). IR spectra were recorded using an Infralum FT-801 FTIR spectrometer (ISP SB RAS, Novosibirsk, Russia). The samples were analyzed as KBr disk solids and the more important frequencies are shown in cm−1. 1H and 13C NMR spectra were recorded in chloroform-d3 (CDCl3) or dimethylsulfoxide-d6 (DMSO-d6) solutions at 25 °C with a 600-MHz NMR spectrometer (JEOL Ltd., Tokyo, Japan). Peak positions were given in parts per million (ppm), referenced to the appropriate solvent residual peak, and signal multiplicities were collected by: s (singlet), d (doublet), dd (doublet of doublets), ddd (doublet of doublet of doublets), t (triplet), q (quartet), br.s (broad singlet), and m (multiplet). MALDI mass spectra were recorded using a Bruker autoflex speed instrument operating in positive-ion reflectron mode (Bremen, Germany). The data of compound 5a were collected at room temperature using an STOE diffractometer Pilatus100K detector, focusing on mirror collimation Cu Kα (1.54086 Å) radiation, in rotation method mode. STOE X-AREA software was used for cell refinement and data reduction. Data collection and image processing were performed with X-Area 1.67 (STOE & Cie GmbH, Darmstadt, Germany, 2013). Intensity data were scaled with LANA (part of X-Area) in order to minimize the differences in intensities of symmetry-equivalent reflections (multiscan method).

3.1.1. Synthesis of 2-Alkyl-10-chloro-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridines 3a–d

Phosphorus chloride was added dropwise in a volume of 10 mL to anthranilic acids 1a–c (0.0146 mol), which was then added in 1 equivalent excess of (0.0146 mol) 1-alkylpiperidine-4-one 2a,b. Next, the reaction was stirred for 4 h at 100 °C and controlled by TLC in an ethyl acetate—hexane (1:1) system on Silufol plates. After cooling, the resulting solution was neutralized with dilute NaOH solution to pH = 9–10, and the product was extracted with CH2Cl2. The organic phase was dried over anhydrous sodium sulfate and concentrated on a rotary evaporator. The product was obtained by crystallization from diethyl ether.
2-benzyl-10-chloro-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine (3a). Light-yellow crystals, yield 92%, m.p.= 120–121 °C. 1H NMR (600 MHz, CDCl3) δ (ppm): 8.16 (1H, dd, J = 8.3, 1.4 Hz), 8.00 (1H, dd, J = 8.5, 1.1 Hz), 7.69 (1H, ddd, J = 8.3, 6.8, 1.4 Hz), 7.55 (1H, ddd, J = 8.2, 6.9, 1.2 Hz), 7.42 (2H, d, J = 7.0 Hz), 7.37 (2H, t, J = 7.6 Hz), 7.31 (1H, t, J = 7.3 Hz), 3.93 (2H, s), 3.82 (2H, s), 3.24 (2H, t, J = 5.9 Hz), 2.90 (2H, t, J = 6.0 Hz). 13C NMR (150 MHz, CDCl3), δ (ppm): 157.4, 147.5, 139.9, 138.1, 129.9, 129.4(2C), 129.1, 128.8(2C), 127.7, 127.1, 127.0, 125.4, 123.9, 62.8, 54.5, 49.9, 34.0. HRMS (MALDI+) m/z calcd for C19H17ClN2 in form of [M + H]+ ion 309.1159, found: 309.1176.
2-benzyl-8-bromo-10-chloro-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine (3b). Brown crystals, yield 86%. m.p. = 138–139 °C. 1H NMR (600 MHz, CDCl3) δ (ppm): 8.32 (1H, d, J = 2.3 Hz), 7.85 (1H, d, J = 8.8 Hz), 7.75 (1H, dd, J = 8.9, 2.2 Hz), 7.41 (2H, d, J = 7.5 Hz), 7.37 (2H, t, J = 7.4 Hz), 7.32 (1H, d, J = 7.1 Hz), 3.92 (2H, s), 3.82 (2H, s), 3.21 (2H, t, J = 6.0 Hz), 2.90 (2H, t, J = 5.9 Hz). 13C NMR (150 MHz, CDCl3) δ (ppm): 157.8, 145.8, 138.5, 133.3, 130.6(2C), 129.2(2C), 128.6(2C), 127.6, 126.4, 126.1(2C), 121.0, 62.6, 54.3, 49.6, 33.8. HRMS (MALDI+) m/z calcd for C19H16BrClN2 in form of [M + H]+ ion 387.0264, found: 387.0280. The observed characterization data (1H) were consistent with those previously reported in the literature [46].
2-methyl-10-chloro-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine (3c). Light-yellow crystals, yield 68%, m.p. = 94–95 °C. 1H NMR (600 MHz, CDCl3) δ(ppm): 8.18 (1H, dd, J = 8.4, 0.9 Hz), 8.00 (1H, dd, J = 8.4, 0.6 Hz), 7.70 (1H, ddd, J = 8.4, 6.9, 1.4 Hz), 7.56 (1H, ddd, J = 8.2, 6.8, 1.2 Hz), 3.84 (2H, s), 3.28 (2H, t, J = 6.0 Hz), 2.87 (2H, t, J = 6.0 Hz), 2.58 (3H, s). 13C NMR (150 MHz, CDCl3) δ (ppm): 156.6, 147.2, 139.5, 129.8, 128.9, 126.8, 126.6, 125.1, 123.7, 56.0, 52.5, 46.1, 33.8. HRMS (MALDI+) m/z calcd for C13H13ClN2 in form of [M + H]+ ion 233.0846, found: 233,0831.
2-methyl-8-nitro-10-chloro-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine (3d). Yellow crystals, yield 75%, m.p. = 172–173 °C. 1H NMR (600 MHz, CDCl3) δ (ppm): 9.10 (1H, d, J = 2.5 Hz), 8.43 (1H, dd, J = 9.2, 2.5 Hz), 8.09 (1H, d, J = 9.2 Hz), 3.88 (2H, s), 3.31 (2H, t, J = 5.9 Hz), 2.92 (2H, t, J = 6.0 Hz), 2.61 (3H, s). 13C NMR (150 MHz, CDCl3) δ (ppm): 161.2, 149.4, 146.0, 141.3, 131.1, 128.9, 124.6, 123.5, 121.3, 56.0, 52.2, 46.1, 34.2. HRMS (MALDI+) m/z calcd for C13H12ClN3O2 in form of [M + H]+ ion 278.0696, found: 278.0704.

3.1.2. Synthesis of 2-Vinyl-10-chloro-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridines 4a,b and 1-Vinyl-10-chloro-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridines 4c

To a solution of 0.2 g of benzonaphthyridines 3a,b in 5 mL of methanol with 0.5 mL of formic acid was added a 1.2 equivalent of activated alkyne. The reaction was kept at room temperature for 10 days. Compounds 4a,b spontaneously fell out of the reaction mass in the form of crystals and were released by filtration.
To a solution of 0.2 g of benzonaphthyridines 3d in 5 mL of trifluoroethanol with 0.5 mL was added a 1.2 equivalent of activated alkyne. The reaction was kept at room temperature for 15 days. The product was obtained by crystallization from diethyl ether.
Methyl (2E)-3-(10-chloro-3,4-dihydrobenzo[b][1,6]naphthyridin-2(1H)-yl)prop-2-enoate (4a). White crystals, yield 59%. m.p. = 171–172 °C. 1H NMR (600 MHz, CDCl3) δ (ppm): 8.21 (1H, dd, J = 8.4, 1.4 Hz), 8.02 (1H, d, J = 8.5 Hz), 7.76 (1H, ddd, J = 8.3, 6.8, 1.4 Hz), 7.63 (1H, d, J = 6.4 Hz), 7.65–7.61 (2H, m), 4.89 (1H, d, J = 13.2 Hz), 4.57 (2H, s), 3.71 (3H, s), 3.70–3.69 (2H, m), 3.27 (2H, t, J = 6.0 Hz). 13C NMR (150 MHz, CDCl3) δ (ppm): 169.8, 155.5, 151.4, 147.4, 130.5, 129.1, 129.1, 127.6, 125.3, 123.8, 86.5, 50.9. HRMS (MALDI+) m/z calcd for C16H15ClN2O2 in form of [M + H]+ ion 303.0900, found: 303.0911.
Methyl (2E)-3-(8-bromo-10-chloro-3,4-dihydrobenzo[b][1,6]naphthyridin-2(1H)-yl)prop-2-enoate (4b). Yellow crystals, yield 67%. m.p. =194–195 °C. 1H NMR (600 MHz, CDCl3) δ (ppm): 8.36 (1H, d, J = 2.1 Hz), 7.88 (1H, d, J = 9.0 Hz), 7.81 (1H, dd, J = 9.0, 2.1 Hz), 7.62 (1H, d, J = 13.1 Hz), 4.90 (1H, d, J = 13.1 Hz), 4.56 (2H, s), 3.71 (3H, s), 3.69 (2H, m), 3.26 (2H, t, J = 6.0 Hz). 13C NMR (150 MHz, CDCl3) δ (ppm): 169.8, 156.1, 151.3, 146.0, 134.1, 130.9, 126.4, 126.1, 121.8, 86.8, 50.9. HRMS (MALDI+) m/z calcd for C16H14BrClN2O2 in form of [M + H]+ ion 381.0005, found: 381.0014.
(3E)-4-(10-chloro-2-methyl-8-nitro-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridin-1-yl)but-3-en-2-one (4c). White crystals, yield 62%. 1H NMR (600 MHz, CDCl3) δ (ppm): 9.13 (1H, d, J = 2.2 Hz), 8.49 (1H, dd, J = 9.2, 2.5 Hz), 8.13 (1H, d, J = 9.2 Hz), 6.82 (1H, dd, J = 16.0, 7.0 Hz), 6.04 (1H, d, J = 15.9 Hz), 4.86 (1H, d, J = 6.9 Hz), 3.41–3.34 (1H, m), 3.27–3.22 (1H, m), 3.16 (1H, dd, J = 4.8, 2.4 Hz), 3.03–2.99 (1H, m), 2.60 (3H, s), 2.26 (3H, s). 13C NMR (150 MHz, CDCl3) δ (ppm): 197.8, 161.2, 149.5, 146.0, 143.0, 140.9, 134.6, 131.0, 128.8, 124.7, 123.9, 121.5, 62.0, 45.6, 42.4, 31.4, 27.7. HRMS (MALDI+) m/z calcd for C17H16ClN3O3 in form of [M + H]+ ion 346.0958, found: 346.0981.

3.1.3. Synthesis of 2-Alkyl-10-chloro-1-phenylethynyl-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridines 5a–h

A solution of 3a,c (0.5 g) in 10 mL of THF was cooled to 0 °C, then a 1.5 equivalent excess of DIAD (diisopropylazodicarboxylate) was added. The mixture was stirred at room temperature for 1 h. After cooling it again to 0 °C, a 3 equivalent excess of the appropriate phenylacetylene and CuI catalyst were added. The reaction was stirred at room temperature and controlled by TLC in an ethyl acetate-hexane (1:5) system on Silufol plates. The product was separated by column chromatography.
2-benzyl-10-chloro-1-phenylethynyl-1,2,3,4-tetrahydrobenzo[b][1,6]naphthridine (5a). Colorless crystals, yield 24%. m.p. = 139–140 °C. 1H NMR (600 MHz, CDCl3) δ (ppm): 8.22 (1H, d, J = 8.3 Hz), 8.01 (1H, d, J = 8.3 Hz), 7.72 (1H, t, J = 7.6 Hz), 7.57 (1H, t, J = 7.7 Hz), 7.50–7.43 (4H, m), 7.38 (2H, t, J = 7.5 Hz), 7.34–7.28 (4H, m), 5.31 (1H, s), 4.09 (1H, d, J = 13.0 Hz), 3.91 (1H, d, J = 13.1 Hz), 3.35–3.41 (1H, m), 3.31 (1H, td, J = 11.5, 3.6 Hz), 3.18 (1H, dd, J = 16.6, 3.6 Hz), 3.08 (1H, dd, J = 11.6, 6.7 Hz). 13C NMR (150 MHz, CDCl3) δ (ppm): 156.7, 147.6, 140.6, 138.0, 131.9(2C), 130.2, 129.2(2C), 128.8, 128.6(2C), 128.4(2C), 128.3, 127.6, 126.9, 125.3, 124.2(2C), 122.8, 87.5, 84.3, 59.4, 52.8, 44.8, 33.4. IR spectrum (KBr), υ/cm−1: 2223.1 (-C≡C-). HRMS (MALDI+) m/z calcd for C27H21ClN2 in form of [M + H]+ ion 409.1471, found: 409.1483.
2-benzyl-10-chloro-1-[(3-methoxyphenyl)ethynyl]-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine (5b). Oil, yield 35%. 1H NMR (600 MHz, CDCl3) δ (ppm): 8.21 (1H, d, J = 8.4 Hz), 8.01 (1H, d, J = 8.5 Hz), 7.71 (1H, t, J = 7.7 Hz), 7.57 (1H, t, J = 7.8 Hz), 7.47 (2H, d, J = 7.4 Hz), 7.37 (2H, t, J = 7.5 Hz), 7.31 (1H, t, J = 7.3 Hz), 7.20 (1H, t, J = 8.0 Hz), 7.05 (1H, d, J = 7.6 Hz), 6.96 (1H, s), 6.86 (1H, dd, J = 8.2, 2.6 Hz), 5.30 (1H, s), 4.08 (1H, d, J = 13.1 Hz), 3.90 (1H, d, J = 13.1 Hz), 3.78 (3H, s), 3.41–3.34(1H, m), 3.30 (1H, td, J = 11.6, 3.6 Hz), 3.18 (1H, dd, J = 16.4, 3.1 Hz), 3.07 (1H, dd, J = 11.5, 6.8 Hz). 13C NMR (150 MHz, CDCl3) δ (ppm): 159.4, 156.7, 138.0, 130.3, 129.5, 129.2(2C), 128.8, 128.7(2C), 127.6, 127.5, 127.0, 125.4, 124.6(2C), 124.2, 123.8, 116.9(2C), 115.0, 87.5, 84.1, 59.4, 55.4, 52.9, 44.8, 33.3. IR spectrum (KBr), υ/cm−1: 2222.9 (-C≡C-). HRMS (MALDI+) m/z calcd for C28H23ClN2O in form of [M + H]+ ion 439.1577, found: 439.1558.
10-chloro-2-methyl-1-phenylethynyl-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine (5c). Oil, yield 32%. 1H NMR (600 MHz, CDCl3) δ(ppm): 8.23 (1H, d, J = 8.4 Hz), 8.01 (1H, d, J = 8.3 Hz), 7.72 (1H, t, J = 7.6 Hz), 7.58 (1H, t, J = 7.6 Hz), 7.39 (2H, dd, J = 7.4, 2.2 Hz), 7.25 (3H, m), 5.30 (1H, s), 3.41 (1H, ddd, J = 17.4, 11.7, 7.3 Hz), 3.28 (1H, td, J = 11.8, 4.2 Hz), 3.18 (1H, dd, J = 17.3, 4.1 Hz), 2.98 (1H, dd, J = 12.0, 7.3 Hz), 2.69 (3H, s). IR spectrum (KBr), υ/cm−1: 2225.8 (-C≡C-). HRMS (MALDI+) m/z calcd for: C21H17ClN2 in form of [M + H]+ ion 333.1159, found: 333.1142.
10-chloro-2-methyl-1-[3-(methoxyphenyl)ethynyl]-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine (5d). Oil, yield 85%. 1H NMR (600 MHz, CDCl3) δ (ppm): 8.23 (1H, d, J = 8.5 Hz), 8.04 (1H, d, J = 8.4 Hz), 7.73 (1H, t, J = 7.7 Hz), 7.59 (1H, t, J = 7.7 Hz), 7.17 (1H, t, J = 8.0 Hz), 6.99 (1H, d, J = 7.7 Hz), 6.91 (1H, s), 6.84 (1H, dd, J = 8.5, 2.6 Hz), 5.35 (1H, s), 3.75 (3H, s), 3.49 (1H, ddd, J = 18.2, 11.8, 7.3 Hz), 3.34 (1H, td, J = 11.9, 4.5 Hz), 3.23 (1H, dd, J = 17.5, 4.3 Hz), 3.05 (1H, dd, J = 12.1, 7.2 Hz), 2.74 (3H, s). 13C NMR (150 MHz, CDCl3) δ (ppm): 159.3, 155.4, 147.4, 140.9, 130.6, 129.5, 128.7, 127.2, 125.4, 124.5(2C), 124.2, 123.4, 116.8, 115.2, 88.1, 82.8, 55.4, 54.6, 46.9, 43.1, 32.6. IR spectrum (KBr), υ/cm−1: 2216.1 (-C≡C-). HRMS (MALDI+) m/z calcd for: C22H19ClN2O in form of [M + H]+ ion 363.1264, found: 363.1281.
10-chloro-2-methyl-1-[4-(methoxyphenyl)ethynyl]-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine (5e). Oil, yield 88%. 1H NMR (600 MHz, CDCl3) δ(ppm): 8.23 (1H, d, J = 8.3 Hz), 8.01 (1H, d, J = 8.4 Hz), 7.72 (1H, ddd, J = 8.3, 6.9, 1.4 Hz), 7.58 (1H, ddd, J = 8.2, 6.8, 1.2 Hz), 7.33 (2H, d, J = 8.9 Hz), 6.79 (2H, d, J = 8.9 Hz), 5.28 (1H, s), 3.77 (3H, s), 3.46–3.34 (1H, m), 3.28 (1H, td, J = 11.7, 4.3 Hz), 3.18 (1H, dd, J = 17.4, 3.4 Hz), 2.97 (1H, dd, J = 11.9, 7.3 Hz), 2.68 (3H, s). 13C NMR (150 MHz, CDCl3) δ (ppm): 159.7, 156.1, 147.6, 140.4, 133.3(2C), 130.2, 128.9, 127.6, 126.9, 125.4, 124.3, 114.9, 113.9(2C), 87.5, 82.3, 55.4, 54.7, 46.9, 43.2, 33.1. IR spectrum (KBr), υ/cm−1: 2222.3 (-C≡C-). HRMS (MALDI+) m/z calcd for: C22H19ClN2O in form of [M + H]+ ion 363.1264, found: 363.1279.
2-benzyl-10-chloro-1-{[4-(trifluoromethyl)phenyl]ethynyl}-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine (5f). Oil, yield 61%. 1H NMR (600 MHz, CDCl3) δ(ppm): 8.24 (1H, d, J = 8.6 Hz), 8.05 (1H, d, J = 8.6 Hz), 7.75 (1H, t, J = 7.6 Hz), 7.60 (1H, t, J = 7.7 Hz), 7.42 (2H, J = 8.5 Hz), 7.12 (2H, d, J = 8.4 Hz), 5.34 (1H, s), 3.52–3.46 (1H, m), 3.33–3.26 (1H, m), 3.23 (1H, dd, J = 17.4, 4.1 Hz), 3.05 (1H, dd, J = 12.2, 7.4 Hz), 2.73 (3H, s). 13C NMR (150 MHz, CDCl3) δ (ppm): 155.5, 149.2, 133.5(2C), 130.6, 128.7, 127.32, 125.4, 124.3(2C), 121.4, 121.3, 120.9(2C), 119.6, 86.8, 84.2, 60.5, 54.6, 47.0, 43.1, 32.6. IR spectrum (KBr), υ/cm−1: 2221.2 (-C≡C-). HRMS (MALDI+) m/z calcd for: C22H16ClN2F3 in form of [M + H]+ ion 401.1032, found: 401.1041.
10-chloro-1-[(4-fluorophenyl)ethynyl]-2-methyl-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine (5g). Oil, yield 44%. 1H NMR (600 MHz, CDCl3) δ (ppm): 8.23 (1H, d, J = 8.4 Hz), 8.03 (1H, d, J = 8.5 Hz), 7.73 (1H, t, J = 7.3 Hz), 7.59 (1H, t, J = 7.6 Hz), 7.40–7.35 (2H, m), 6.99–6.93 (2H, m), 5.31 (1H, s), 3.45 (1H, ddd, J = 17.4, 11.7, 7.3 Hz), 3.29 (1H, td, J = 11.8, 4.4 Hz), 3.20 (1H, dd, J = 17.4, 4.3 Hz), 3.02 (1H, dd, J = 11.9, 7.2 Hz), 2.71 (3H, s). 13C NMR (150 MHz, CDCl3) δ (ppm): 163.3, 161.6, 155.6, 147.3, 140.5, 133.7, 133.6, 130.2, 128.6, 126.9, 125.1, 124.0, 118.5, 115.5, 115.4, 86.6, 83.0, 54.5, 46.8, 42.9, 32.6. IR spectrum (KBr), υ/cm−1: 2227.1 (-C≡C-). IR spectrum (KBr), υ/cm−1: 2227.1 (-C≡C-). HRMS (MALDI+) m/z calcd for C21H16ClFN2 in form of [M + H]+ ion 351.1064, found: 351.1049.
10-chloro-1-[(4-chlorophenyl)ethynyl]-2-methyl-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine (5h). Oil, yield 59%. 1H NMR (600 MHz, CDCl3) δ(ppm): 8.24 (1H, dd, J = 8.5, 0.9 Hz), 8.11 (1H, d, J = 8.4 Hz), 7.78 (1H, ddd, J = 8.3, 6.9, 1.4 Hz), 7.63 (1H, ddd, J = 8.3, 6.9, 1.2 Hz), 7.32 (2H, d, J = 8.7 Hz), 7.25 (2H, d, J = 6.7 Hz), 5.44 (1H, s), 3.67–3.58 (1H, m), 3.45–3.36 (1H, m), 3.32 (1H, dd, J = 17.8, 4.4 Hz), 3.17 (1H, m), 2.81 (3H, s). IR spectrum (KBr), υ/cm−1: 2223.0 (-C≡C-). HRMS (MALDI+) m/z calcd for: C21H16Cl2N2 in form of [M + H]+ ion 367.0769, found: 367.0780.

3.1.4. Synthesis of Compounds 6a–f

The appropriate tetrahydrobenzonaphthyridines 5c,d,f,g were dissolved in isopropanol at room temperature and cooled for 10 min in the freezer, then a 1.2 equivalent of activated alkyne was added and the mixture was stored in the refrigerator for 1 week. The reaction was controlled by TLC in an ethyl acetate/n-hexane 1:1 system on Silufol plates. The product was separated by column chromatography.
Methyl (2E)-3-{10-chloro-1-[(4-fluorophenyl)ethynyl]-2-methyl-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridin-1-yl}prop-2-enoate (6a). Oil, yield 27%. 1H NMR (600 MHz, CDCl3) δ (ppm): 8.26 (1H, d, J = 8.6, 1.4, 0.6 Hz), 7.99 (1H, d, J = 8.5, 0.6 Hz), 7.74 (1H, t, J = 7.6 Hz), 7.56 (1H, t, J = 7.6 Hz), 7.44 (2H, dd J = 8.8, 5.3 Hz), 7.00 (2H, t, J = 8.7 Hz), 6.83 (1H, d, J = 15.6 Hz), 6.50 (1H, d, J = 15.6 Hz), 3.76 (3H, s), 3.53–3.49 (1H, m), 3.17–3.12 (2H, m), 3.07–3.03 (1H, m), 2.53 (3H, s). 13C NMR (150 MHz, CDCl3) δ (ppm): 166.9, 163.8, 162.1, 156.5, 147.5, 142.8, 134.1, 134.1, 131.0, 128.9, 128.7, 127.4, 126.4, 125.2, 124.7, 124.6, 118.8, 116.0, 88.3, 83.46, 63.6, 52.1, 48.0, 40.0, 35.1. IR spectrum (KBr), υ/cm−1: 2224.3 (-C≡C-); 1724 (C = O). HRMS (MALDI+) m/z calcd for: C25H20ClFN2O2 in form of [M + H]+ ion 435.1276, found: 435.1261.
Methyl (2E)-3-{10-chloro-1-[(3-methoxyphenyl)ethynyl]-2-methyl-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridin-1-yl}prop-2-enoate (6b). Oil, yield 22%. 1H NMR (600 MHz, CDCl3) δ (ppm): 8.27 (1H, d, J = 8.1 Hz), 7.99 (1H, d, J = 8.3 Hz), 7.73 (1H, t, J = 7.6 Hz), 7.57 (1H, t, J = 7.7 Hz), 7.21 (1H, t, J = 8.0 Hz), 7.07 (1H, d, J = 7.6 Hz), 6.98 (1H, s), 6.88 (1H, dd, J = 8.2, 2.7 Hz), 6.83 (1H, d, J = 15.6 Hz), 6.51 (1H, d, J = 15.6 Hz), 3.79 (3H, s), 3.75 (3H, s), 3.51 (1H, ddd, J = 17.9, 12.0, 6.1 Hz), 3.20–3.12 (2H, m), 3.05 (1H, ddd, J = 11.7, 6.1, 1.9 Hz), 2.53 (3H, s). 13C NMR (150 MHz, CDCl3) δ (ppm): 166.7, 159.4, 156.3, 147.3, 142.6, 130.7, 130.2, 129.5, 129.4, 128.6, 128.5, 127.1, 128.8, 126.2, 124.9, 124.5, 123.4, 116.9, 115.1, 89.0, 83.3, 63.4, 60.5, 55.4, 51.9, 47.8. IR spectrum (KBr), υ/cm−1: 2224.3 (-C≡C-); 1724 (C = O). HRMS (MALDI+) m/z calcd for C26H23ClN2O3 in form of [M + H]+ ion 447.1476, found: 447.1460.
(3E)-4-[10-chloro-2-methyl-1-(phenylethynyl)-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridin-1-yl]but-3-en-2-one (6c). White crystals, yield 37%, m.p. = 154–155 °C. 1H NMR (600 MHz, CDCl3) δ (ppm): 8.28 (1H, d, J = 8.5 Hz), 8.01 (1H, d, J = 8.5 Hz), 7.75 (1H, ddd, J = 8.3, 6.8, 1.3 Hz), 7.58 (1H, ddd, J = 8.3, 6.8, 1.2 Hz), 7.47 (2H, dd, J = 7.4, 1.9 Hz), 7.32–7.30 (3H, m), 6.73 (1H, d, J = 16.1 Hz), 6.63 (1H, d, J = 16.1 Hz), 3.59–3.47 (1H, m), 3.24–3.11 (2H, m), 3.06 (1H, ddd, J = 13.1, 6.1, 2.5 Hz), 2.53 (3H, s), 2.31 (3H, s). 13C NMR (150 MHz, CDCl3) δ (ppm): 198.6, 156.0, 147.1, 146.2, 142.4, 134.2(2C), 131.8(2C), 130.6, 128.6, 128.5, 128.3(2C), 127.0(2C), 126.0, 124.3, 122.2, 89.3, 82.9, 63.5, 47.7, 39.6, 34.7. IR spectrum (KBr), υ/cm−1: 2219.3 (-C≡C-); 1675.5 (C = O). HRMS (MALDI+) m/z calcd for: C25H21ClN2O in form of [M + H]+ ion 401.1421, found: 401.1411.
(3E)-4-{10-chloro-1-[(3-methoxyphenyl)ethynyl]-2-methyl-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridin-1-yl}but-3-en-2-one (6d). Oil, yield 34%. 1H NMR (600 MHz, CDCl3) δ(ppm): 8.28 (1H, ddd, J = 8.5, 1.3, 0.6 Hz), 8.01 (1H, dd, J = 8.5, 0.6 Hz), 7.75 (1H, ddd, J = 8.4, 6.8, 1.4 Hz), 7.58 (1H, ddd, J = 8.3, 6.8, 1.2 Hz), 7.21 (1H, ddd, J = 8.2, 7.6, 0.4 Hz), 7.07 (1H, ddd, J = 7.6, 1.4, 1.0 Hz), 6.97 (1H, dd, J = 2.7, 1.3 Hz), 6.88 (1H, ddd, J = 8.4, 2.6, 1.0 Hz), 6.72 (1H, d, J = 16.1 Hz), 6.62 (1H, d, J = 16.1 Hz), 3.79 (3H, s), 3.53 (1H, ddd, J = 16.0, 11.6, 6.2 Hz), 3.23–3.11 (2H, m), 3.06 (1H, ddd, J = 13.4, 6.2, 2.8 Hz), 2.53 (3H, s), 2.31 (3H, s). 13C NMR (150 MHz, CDCl3) δ (ppm): 166.8, 159.5, 156.3, 147.3, 142.7, 130.8, 129.5, 128.7, 128.6, 127.1, 126.2, 125.0, 124.6, 124.5, 123.5, 122.1, 116.9, 115.2, 111.8, 89.0, 83.3, 63.4, 60.5, 55.4, 51.9, 47.8. IR spectrum (KBr), υ/cm−1: 2219.3 (-C≡C-); 1723.8 (C = O). HRMS (MALDI+) m/z calcd for: C26H23ClN2O2 in form of [M + H]+ ion 431.1526, found: 431.1539.
(3E)-4-(10-chloro-2-methyl-1-{[4-(trifluoromethyl)phenyl]ethynyl}-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridin-1-yl)but-3-en-2-one (6e). Oil, yield 42%. 1H NMR (600 MHz, CDCl3) δ (ppm): 8.28 (1H, d, J = 8.5 Hz), 8.01 (1H, d, J = 8.5 Hz), 7.76 (1H, t, J = 7.7 Hz), 7.64–7.55 (1H, m), 7.49 (2H, d, J = 8.4 Hz), 7.16 (2H, d, J = 8.8 Hz), 6.69 (1H, d, J = 16.1 Hz), 6.62 (1H, d, J = 16.1 Hz), 3.56–3.50 (1H, m), 3.17 (2H, m), 3.07 (1H, m), 2.52 (3H, s), 2.31 (3H, s). IR spectrum (KBr), υ/cm−1: 2220.9 (-C≡C-); 1721.4 (C = O). HRMS (MALDI+) m/z calcd for: C26H20ClF3N2O in form of [M + H]+ ion 469.1295, found: 469.1301.
Methyl 5-(4-chloro-2-ethenylquinolin-3-yl)-4-(4-fluorobenzyl)-1-methyl-1H-pyrrole-3-carboxylate (7). Oil, yield 3%. 1H NMR (600 MHz, CDCl3) δ(ppm): 8.07 (1H, d, ddd, J = 8.5, 1.4, 0.7 Hz), 7.99 (1H, d, J = 8.5 Hz), 7.69 (1H, ddd, J = 8.4, 6.9, 1.4 Hz), 7.56 (1H, ddd, J = 8.3, 6.9, 1.1 Hz), 7.25 (1H, s), 7.07–7.04 (2H, m), 6.74 (2H, t, J = 8.8 Hz), 6.68 (1H, dd, J = 16.7, 10.6 Hz), 6.32 (1H, dd, J = 16.8, 2.0 Hz), 5.42 (1H, dd, J = 10.6, 1.9 Hz), 4.40 (2H, s), 3.60 (3H, s), 3.46 (3H, s). 13C NMR (150 MHz, CDCl3) δ (ppm): 165.0, 155.6, 133.7, 132.0, 132.0, 130.9, 130.9, 130.3(2C), 129.9, 128.2(2C), 127.7(2C), 126.9, 125.7, 124.5, 124.5, 124.5, 122.4, 114.5, 114.3, 51.0, 35.5, 26.8. HRMS (MALDI+) m/z calcd for: C25H20ClFN2O2 in form of [M + H]+ ion 435.1276, found: 435.1268.

3.1.5. Synthesis of 2-Benzyl-10-chloro-1-(indol-3-yl)-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridines 8a–d

A solution of 3a (0.5 g) in 10 mL of THF was cooled to 0 °C, then a 1.2 equivalent excess of DIAD (diisopropylazodicarboxylate) was added. The mixture was stirred at room temperature for 1 h. After cooling it again to 0 °C, a 1.5 equivalent excess of the appropriate indole was added. The reaction was stirred at room temperature and controlled by TLC in an ethyl acetate/hexane (1:1) system on Silufol plates. The product was separated by column chromatography.
2-benzyl-10-chloro-1-(5-methoxy-1H-indol-3-yl)-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine (8a). Yellow foamed oil, yield 61%. 1H NMR (600 MHz, CDCl3) δ (ppm): 8.17 (1H, d, J = 7.6 Hz), 8.08 (1H, d, J = 8.4 Hz), 8.03 (1H, s), 7.74 (1H, ddd, J = 8.4, 6.9, 1.3 Hz), 7.57 (1H, ddd, J = 8.1, 6.9, 1.0 Hz), 7.44 (2H, d, J = 7.2 Hz), 7.37 (2H, t, J = 7.5 Hz), 7.33–7.29 (1H, m), 7.20 (1H, d, J = 8.7 Hz), 7.01 (1H, d, J = 2.4 Hz), 6.84 (1H, dd, J = 8.7, 2.5 Hz), 6.36 (1H, d, J = 2.5 Hz), 5.76 (1H, s), 4.00 (1H, d, J = 13.2 Hz), 3.79 (3H, s), 3.65 (1H, d, J = 13.2 Hz), 3.44–3.33 (2H, m), 3.09–3.05 (1H, m), 3.03–2.99 (1H, m). 13C NMR (150 MHz, CDCl3) δ (ppm): 157.5, 154.2, 147.5, 141.9, 139.2, 131.4, 130.0(2C), 129.6, 129.3(2C), 128.8, 128.6(2C), 127.8, 127.4, 126.9(2C), 125.0, 124.2, 115.3, 112.9, 111.9, 101.3, 57.5, 55.9, 42.5, 29.1. HRMS (MALDI+) m/z calcd for: C28H24ClN3O in form of [M + H]+ ion 454.1686, found: 454.1669.
2-benzyl-10-chloro-1-(1H-indol-3-yl)-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine (8b). Compound was isolated in mixture with hydrazine 9. Yellow foamed oil, yield 48%. 1H NMR 1H NMR (600 MHz, CDCl3) δ (ppm): 8.31 (1H, s), 8.22 (1H, s), 8.16 (1H, d, J = 8.3 Hz), 8.08 (1H, d, J = 8.4 Hz), 7.73 (1H, t, J = 7.7 Hz), 7.62 (1H, d, J = 8.0 Hz), 7.56 (1H, t, J = 7.6 Hz), 7.41 (1H, d, J = 7.5 Hz), 7.38–7.33 (2H, m), 7.34–7.28 (3H, m), 7.19 (1H, t, J = 7.6 Hz), 7.15–7.09 (2H, m), 6.42 (1H, s), 5.84 (1H, s), 4.01 (1H, d, J = 13.3 Hz), 3.61 (1H, d, J = 13.2 Hz), 3.39 (1H, ddd, J = 18.4, 11.8, 7.3 Hz), 3.26 (1H, td, J = 12.5, 5.0 Hz), 3.10 (1H, dd, J = 17.9, 4.8 Hz), 2.94 (1H, dd, J = 13.1, 7.3 Hz). HRMS (MALDI+) m/z calcd for: C27H22ClN3 in form of [M + H]+ ion 424.1581, found: 424.1591.
2-benzyl-10-chloro-1-(5-chloro-1H-indol-3-yl)-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine (8c). Compound was isolated in mixture with hydrazine 9. Yellow foamed oil, yield 51%. 1H NMR (600 MHz, CDCl3) δ (ppm): 8.34 (1H, s), 8.17–8.16 (2H, m), 8.08 (1H, d, J = 8.4 Hz), 7.75 (1H, ddd, J = 8.3, 6.7, 1.4 Hz), 7.61–7.56 (2H, m), 7.54 (1H, d, J = 2.1 Hz), 7.42–7.39 (5H, m), 7.35–7.33 (2H, m), 7.24 (2H, d, J = 8.6 Hz), 7.14 (2H, dd, J = 8.6, 2.0 Hz), 6.38 (1H, d, J = 2.4 Hz), 5.73 (1H, s), 3.97 (1H, d, J = 13.1 Hz), 3.62 (1H, d, J = 13.1 Hz), 3.39 (1H, ddd, J = 18.4, 12.0, 7.2 Hz), 3.29 (1H, td, J = 12.7, 4.9 Hz), 3.06 (1H, dd, J = 17.9, 4.8 Hz), 3.01 (1H, dd, J = 13.4, 7.1 Hz). HRMS (MALDI+) m/z calcd for: C27H21Cl2N3 in form of [M + H]+ ion 458.1191, found: 458.1183.
2-benzyl-10-chloro-1-(5-bromo-1H-indol-3-yl)-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine (8d). Compound was isolated in mixture with hydrazine 9. Yellow foamed oil, yield 69%. 1H NMR (600 MHz, CDCl3) δ (ppm): 8.18 (1H, s), 8.17 (1H, dd, J = 8.3, 1.3 Hz), 8.08 (1H, d, J = 8.5 Hz), 7.77–7.72 (2H, m), 7.69 (1H, s), 7.58 (1H, ddd, J = 8.3, 6.8, 1.2 Hz), 7.42 (3H, d, J = 4.4 Hz), 7.37–7.33 (1H, m), 7.27 (1H, d, J = 1.9 Hz), 7.19 (1H, d, J = 8.6 Hz), 6.34 (1H, s), 5.72 (1H, s), 3.96 (1H, d, J = 13.0 Hz), 3.62 (1H, d, J = 13.0 Hz), 3.39 (1H, ddd, J = 18.1, 12.0, 7.2 Hz), 3.30 (1H, td, J = 12.7, 4.9 Hz), 3.06 (1H, dd, J = 17.9, 4.8 Hz), 3.02 (1H, dd, J = 13.3, 7.1 Hz). HRMS (MALDI+) m/z calcd for: C27H21BrClN3 in form of [M + H]+ ion 502.0686, found: 502.0678.

3.1.6. Synthesis of 1-[2-Benzyl-6-chloro-5-(indol-3-yl)-2,5-dihydro-1H-azepino[3,4-b]quinolin-4-yl]ethenones 10a,b

The appropriate compounds 8a,d were dissolved in isopropanol at room temperature and cooled for 10 min in the freezer, then a 1.2 equivalent of activated alkyne was added and the mixture was stored in the refrigerator for 1 week. The reaction was controlled by TLC in an ethyl acetate/hexane 1:1 system on Silufol plates. The compound spontaneously fell out of the reaction mass in the form of crystals and was released by filtration.
1-[(4E)-3-benzyl-7-chloro-6-(5-methoxy-1H-indol-3-yl)-1,2,3,6-tetrahydroazocino[4,5-b]quinolin-5-yl]ethanone (10a). White crystals, yield 87%, m.p. = 147–149 °C. 1H NMR (600 MHz, CDCl3) δ (ppm): 8.33 (1H, s), 8.30 (1H, dd, J = 8.3, 1.3 Hz), 7.94 (1H, d, J = 8.4 Hz), 7.76 (1H, s), 7.72 (1H, ddd, J = 8.4, 6.9, 1.4 Hz), 7.61 (1H, ddd, J = 8.3, 6.9, 1.2 Hz), 7.21 (1H, s), 7.18 (1H, d, J = 8.8 Hz), 7.15–7.10 (1H, m), 7.03 (2H, t, J = 7.7 Hz), 6.74 (1H, dd, J = 8.8, 2.5 Hz), 6.71 (2H, d, J = 7.4 Hz), 6.61 (1H, s), 4.31 (1H, d, J = 15.0 Hz), 4.22 (1H, d, J = 15.0 Hz), 4.22–4.18 (1H, m), 3.47 (3H, s), 3.30 (1H, ddd, J = 16.9, 10.9, 7.4 Hz), 3.17–3.11 (2H, m), 2.42 (3H, s). 13C NMR (150 MHz, CDCl3) δ (ppm): 195.0, 174.5, 171.2, 160.4, 156.5, 153.6, 136.0, 132.3, 132.0, 129.7, 128.7(2C), 128.6, 127.9(2C), 127.3(2C), 127.0, 126.3, 125.9, 125.1(2C), 122.4, 119.3, 112.0, 101.3, 61.8, 60.4, 55.4, 51.0, 39.8, 36.5. IR spectrum (KBr), υ/cm−1: 1695.7 (C = O). HRMS (MALDI+) m/z calcd for: C32H28ClN3O2 in form of [M + H]+ ion 522.1948, found: 522.1956.
1-[(4E)-3-benzyl-7-chloro-6-(5-bromo-1H-indol-3-yl)-1,2,3,6-tetrahydroazocino[4,5-b]quinolin-5-yl]ethanone (10b). White crystals, yield 82%, m.p. =136–137 °C. 1H NMR (600 MHz, CDCl3) δ (ppm): 8.32 (1H, s), 8.30 (1H, d, J = 8.4 Hz), 7.94 (1H, d, J = 8.8 Hz), 7.78–7.69 (2H, m), 7.62 (1H, t, J = 7.6 Hz), 7.24 (1H, s), 7.22–7.14 (2H, m), 7.15 (1H, t, J = 7.4 Hz), 7.06 (2H, t, J = 7.6 Hz), 6.72 (2H, d, J = 7.4 Hz), 6.61 (1H, s), 4.32 (1H, d, J = 15.0 Hz), 4.24 (1H, d, J = 15.0 Hz), 4.16–4.09 (1H, m), 3.31 (1H, ddd, J = 16.7, 10.6, 7.1 Hz), 3.17–3.11 (2H, m), 2.42 (3H, s). 13C NMR (150 MHz, CDCl3) δ (ppm): 194.7, 159.9, 156.1, 146.4, 143.3, 135.8, 135.3, 131.7, 129.7, 128.7, 128.6(2C), 127.8(2C), 127.6, 127.2(2C), 127.0, 125.8, 125.1, 124.9, 122.6, 121.9, 119.7, 112.7, 112.6, 61.8, 50.7, 40.0, 35.9, 25.4. IR spectrum (KBr), υ/cm−1: 1700.3 (C = O). HRMS (MALDI+) m/z calcd for: C31H25BrClN3O in form of [M + H]+ ion 570.0948, found: 570.0969.

3.2. Biochemical Assays

MAO Inhibition

All reagents were purchased from Sigma Aldrich (Milan, Italy). The fluorometric assay was performed as previously described [17] using human recombinant enzymes from baculovirus-infected insect cells, following the formation of fluorescing 4-hydroxyquinoline from the MAO substrate, kynuramine. Assays were performed in triplicate in 96-well plates (Greiner Bio-One GmbH, Frickenhausen, Germany) using an Infinite M1000 multiplate reader (Tecan, Cernusco sul Naviglio (MI), Italy). Results were expressed as mean ± SEM. IC50 values were obtained by nonlinear regression using Prism software (GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego, CA, USA).

4. Conclusions

As a major outcome of this study, novel functionalized 2-alkyl-10-chloro-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridines 3 were synthesized for the first time, specifically 1-phenylethynyl derivatives 5 and 1-indol-3-yl derivatives 8. Moreover, the interaction of these compounds with activated alkynes was studied, revealing that the substituent in the first position played a key role in these reactions and either Stevens rearrangement products or azocino[4,5-b]quinolines were formed.
The 1-phenylethynyl derivatives 5c–h were discovered as MAO inhibitors, showing selectivity toward the human MAO B isoform and potency in the low micromolar range. In particular, the 4-F derivative 5g achieved an IC50 of 1.35 μM in vitro, which was almost equipotent with pargyline (IC50 2.69), a known MAO B irreversible inhibitor that was taken as the positive control. MAO B inhibitors are typically used in the treatment of early symptoms of PD [47], while their efficacy in decreasing oxidative stress may provide neuroprotective effects in the treatment of AD [48]. In this context, compound 5g deserves further optimization studies for improving its pharmacological potential as an effective agent for the treatment of neurodegenerative syndromes.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules28041662/s1, Figures S1–S48: Copies of 1H and 13C NMR spectra. Table S1: Crystal data and structure refinement for 5a.

Author Contributions

Conceptualization, L.N.K., G.R.R., D.D.L., M.C., C.D.A. and L.G.V.; methodology, L.N.K., G.R.R., D.D.L. and L.G.V. (chemistry), and M.C., R.P. and G.L.S. (biological assays); validation, L.N.K., G.R.R., D.D.L., M.C., R.P. and G.L.S.; writing—original draft preparation, L.N.K., G.R.R., D.D.L., L.G.V., M.C., R.P. and C.D.A.; writing—review and editing, all co-authors. All authors have read and agreed to the published version of the manuscript.

Funding

C.D.A., M.C., and R.P. acknowledge the financial support of the Italian Ministry of Education, Universities and Research (PRIN, Grant 201744BNST_004).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

All data presented in this study are available in the article and in Supplementary Materials.

Acknowledgments

This article has been supported by the RUDN University Strategic Academic Leadership Program.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds 3–10 are available from the authors.

References

  1. Lowe, P.A. Comprehensive Heterocyclic Chemistry; Pergamon Press: Oxford, UK, 1984; Volume 1. [Google Scholar]
  2. Devadoss, T.; Sowmya, V.; Bastati, R. Synthesis of 1,6-Naphthyridine and Its Derivatives: A Systematic Review. ChemistrySelect 2021, 15, 3610–3641. [Google Scholar] [CrossRef]
  3. Ghobadi, N.; Nazari, N.; Gholamzadeh, P. The Friedländer reaction: A powerful strategy for the synthesis of heterocycles. Adv. Heterocycl. Chem. 2020, 132, 85–134. [Google Scholar] [CrossRef]
  4. Lavanya, M.; Lin, C.; Mao, J.; Thirumalai, D.; Aabaka, S.R.; Yang, X.; Mao, J.; Huang, Z.; Zhao, J. Synthesis and Anticancer Properties of Functionalized 1,6-Naphthyridines. Top. Curr. Chem. 2021, 379, 13. [Google Scholar] [CrossRef] [PubMed]
  5. Wu, J.F.; Liu, M.M.; Huang, S.X.; Wang, Y. Design and synthesis of novel substituted naphthyridines as potential c-Met kinase inhibitors based on MK-2461. Bioorg. Med. Chem. Lett. 2015, 25, 3251–3255. [Google Scholar] [CrossRef]
  6. Kiselev, E.; Dexheimer, T.; Pommier, Y.; Cushman, M. Design, synthesis, and evaluation of dibenzo[c,h][1,6]naphthyridines as topoisomerase I inhibitors and potential anticancer agents. J. Med. Chem. 2010, 24, 8716–8726. [Google Scholar] [CrossRef]
  7. Galatsis, P.; Yamagata, K.; Wendt, J.A.; Connolly, C.J.; Mickelson, J.W.; Milbank, J.B.; Bove, S.E.; Knauer, C.S.; Brooker, R.M.; Augelli-Szafran, C.E.; et al. Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg. Med. Chem. Lett. 2007, 17, 6525–6528. [Google Scholar] [CrossRef]
  8. Cywin, C.L.; Zhao, B.P.; McNeil, D.W.; Hrapchak, M.; Prokopowicz, A.S., III; Goldberg, D.R.; Morwick, T.M.; Gao, A.; Jakes, S.; Kashem, M.; et al. Discovery and SAR of novel, Naphthyridines as potent inhibitors of spleen tyrosine kinase (SYK). Bioorg. Med. Chem. Lett. 2003, 13, 1415–1418. [Google Scholar] [CrossRef]
  9. Chan, L.; Jin, H.; Stefanac, T.; Lavallée, J.F.; Falardeau, G.; Wang, W. Discovery of 1,6-naphthyridines as a novel class of potent and selective human cytomegalovirus inhibitors. J. Med. Chem. 1999, 42, 3023–3025. [Google Scholar] [CrossRef]
  10. Yu, H.-B.; Yang, F.; Sun, F.; Ma, G.-Y.; Gan, J.-H.; Hu, W.-Z.; Han, B.-N.; Jiao, W.-H.; Lin, H.-W. Cytotoxic Aaptamine Derivatives from the South China Sea Sponge Aaptos aaptos. J. Nat. Prod. 2014, 77, 2124. [Google Scholar] [CrossRef]
  11. Pham, C.-D.; Hartmann, R.; Müller, W.E.G.; Voogd, N.D.; Lai, D.; Proksch, P. Aaptamine Derivatives from the Indonesian Sponge Aaptos suberitoides. J. Nat. Prod. 2013, 76, 103–106. [Google Scholar] [CrossRef]
  12. Rajivgandhi, G.; Ramachandran, G.; Manoharan, N. Marine sponge alkaloid aaptamine enhances the anti-bacterial and anti-cancer activity against ESBL producing Gram negative bacteria and HepG 2 human liver carcinoma cells. Biocatal. Agric. Biotech. 2019, 17, 628–637. [Google Scholar] [CrossRef]
  13. Rudys, S.; Luci, C.R.; Roth, E.P.; Cikotiene, I.; Padron, J.M. Antiproliferative activity of novel benzo[b][1,6]naphthyridines in human solid tumor cell lines. Bioorg. Med. Chem. Lett. 2010, 20, 1504–1506. [Google Scholar] [CrossRef]
  14. Deady, L.W.; Rodemann, T.; Zhuang, L.; Baguley, B.C.; Denny, W.A. Synthesis and Cytotoxic Activity of Carboxamide Derivatives of Benzo[b][1,6]naphthyridines. J. Med. Chem. 2003, 46, 1049–1054. [Google Scholar] [CrossRef]
  15. Fiorito, J.; Vendome, J.; Saeed, F.; Staniszewski, A.; Zhang, H.; Yan, S.; Deng, S.X.; Arancio, O.; Landry, D.W. Identification of a novel 1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine analogue as a potent phosphodiesterase 5 inhibitor with improved aqueous solubility for the treatment of Alzheimer’s disease. J. Med. Chem. 2017, 60, 8858–8875. [Google Scholar] [CrossRef]
  16. Purgatorio, R.; Kulikova, L.N.; Pisani, L.; Catto, M.; de Candia, M.; Carrieri, A.; Cellamare, S.; De Palma, A.; Beloglazkin, A.A.; Reza Raesi, G.; et al. Scouting around 1,2,3,4-Tetrahydrochromeno[3,2-c]pyridin-10-ones for Single- and Multitarget Ligands Directed towards Relevant Alzheimer’s Targets. ChemMedChem 2020, 15, 1947–1955. [Google Scholar] [CrossRef]
  17. Nevskaya, A.A.; Anikina, L.V.; Purgatorio, R.; Catto, M.; Nicolotti, O.; de Candia, M.; Pisani, L.; Borisova, T.N.; Miftyakhova, A.R.; Varlamov, A.V.; et al. Homobivalent lamellarin-like schiff bases: In vitro evaluation of their cancer cell cytotoxicity and multitargeting anti-Alzheimer’s disease potential. Molecules 2021, 26, 359. [Google Scholar] [CrossRef]
  18. Catto, M.; Berezin, A.A.; Lo Re, D.; Loizou, G.; Demetriades, M.; De Stradis, A.; Campagna, F.; Koutentis, P.A.; Carotti, A. Design, synthesis and biological evaluation of benzo[e][1,2,4]triazin-7(1H)-one and [1,2,4]-triazino[5,6,1-jk]carbazol-6-one derivatives as dual inhibitors of beta-amyloid aggregation and acetyl/butyryl cholinesterase. Eur. J. Med. Chem. 2012, 58, 84–97. [Google Scholar] [CrossRef]
  19. Titov, A.A.; Kobzev, M.S.; Catto, M.; de Candia, M.; Gambacorta, N.; Denora, N.; Pisani, L.; Nicolotti, O.; Borisova, T.N.; Varlamov, A.V.; et al. Away from Flatness: Unprecedented Nitrogen-bridged Cyclopenta[a]indene Derivatives as Novel Anti-Alzheimer Multitarget Agents. ACS Chem. Neurosci. 2021, 12, 340–353. [Google Scholar] [CrossRef]
  20. Samadi, A.; de los Ríos, C.; Bolea, I.; Chioua, M.; Iriepa, I.; Moraleda, I.; Bartolini, M.; Andrisano, V.; Gálvez, E.; Valderas, C.; et al. Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer’s disease: Synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine. Eur. J. Med. Chem. 2012, 52, 251–262. [Google Scholar] [CrossRef]
  21. Berlowitz, I.; Egger, K.; Cumming, P. Monoamine Oxidase Inhibition by Plant-Derived β-Carbolines; Implications for the Psychopharmacology of Tobacco and Ayahuasca. Front. Pharmacol. 2022, 13, 886408. [Google Scholar] [CrossRef]
  22. Maleki, B.; Seresht, E.R.; Ebrahimi, Z. Friedlander synthesis of quinolines promoted by polymer-bound sulfonic acid. Org. Prep. Proc. Int. 2015, 47, 149–160. [Google Scholar] [CrossRef]
  23. Chen, Q.P.; Deady, L.W. Synthesis of some benzo[b][1,6]naphthyridines and benzo[b][1,7]naphthyridines. Austral. J. Chem. 1993, 46, 987–993. [Google Scholar] [CrossRef]
  24. Wolinska, E.; Paliakov, E.; Strekowski, L. Facile synthesis of 1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridines. Heteroc. Commun. 2009, 15, 63–66. [Google Scholar] [CrossRef]
  25. Kumar, P.; Aggarwal, T.; Verma, A.K. Chemoselective Azidation of o-Alkynylaldehydes over [3+2] Cycloaddition and Subsequent Staudinger Reaction: Access to Benzonaphthyridines/Naphthyridines. J. Org. Chem. 2017, 82, 6388–6397. [Google Scholar] [CrossRef] [PubMed]
  26. Ravi, M.; Chauhan, P.; Singh, S.; Kant, R.; Yadav, P.P. p-TsOH-promoted synthesis of (E)-6-phenyl-7-styryl-5,6-dihydrodibenzo [b, h][1, 6]naphthyridines via cascade intramolecular aza-Michael addition/Friedlander condensation of 2′-aminochalcones in a SDS/H2O system. RSC Adv. 2017, 6, 48774–48778. [Google Scholar] [CrossRef]
  27. Voskressensky, L.G.; Borisova, T.N.; Listratova, A.; Vorobiev, I.V.; Varlamov, A.V.; Aleksandrov, G.G. First synthesis and x-ray crystal structure of hexahydrobenzo[b]pyrido[3,4,5-de]-1,6-naphthyridines. J. Heteroc. Chem. 2005, 42, 1207–1210. [Google Scholar] [CrossRef]
  28. Voskressensky, L.G.; Vorobiev, I.V.; Borisova, T.N.; Kulikova, L.N.; Bolshov, A.V.; Varlamov, A.V. The first synthesis of tetrahydrobenzo[b]pyrrolo [2,1-f][1, 6]naphthyridine by the Michael addition of butyn-2-one to 1-(2-methoxycarbonylvinyl)tetrahydrobenzo[b][1, 6]naphthyridine. Russ. Chem. Bull. 2010, 59, 1063–1064. [Google Scholar] [CrossRef]
  29. Voskressensky, L.G.; Vorobiev, I.V.; Borisova, T.N.; Varlamov, A.V. Synthesis and reactivity of a novel class of long-lived ammonium ylides: Derivatives of benzo[b]pyrrolo[2, 1-f][1.6]naphthyridine. J. Org. Chem. 2008, 73, 4596–4601. [Google Scholar] [CrossRef]
  30. Kulikova, L.N.; Borisov, R.S.; Voskressensky, L.G. Ring opening in 1,2,3,4-tetrahydrochromeno[3, 2-c]pyridines under the action of electron-deficient alkynes. Mendel. Comm. 2017, 27, 640–641. [Google Scholar] [CrossRef]
  31. Zheng, Q.H.; Meng, W.; Jiang, G.J.; Yu, Z.X. CuI-catalyzed C1-alkynylation of tetrahydroisoquinolines (THIQs) by A3 reaction with tunable iminium ions. Org. Lett. 2013, 15, 5928–5931. [Google Scholar] [CrossRef]
  32. Liu, W.; Liu, S.; Jin, R.; Guo, H.; Zhao, J. Novel strategies for catalytic asymmetric synthesis of C1-chiral 1, 2, 3, 4-tetrahydroisoquinolines and 3, 4-dihydrotetrahydroisoquinolines. Org. Chem. Front. 2015, 2, 288–299. [Google Scholar] [CrossRef]
  33. Zhao, H.; He, W.; Wei, L.; Cai, M. A highly efficient heterogeneous copper-catalyzed three-component coupling of tetrahydroisoquinolines, aldehydes and 1-alkynes. Cat. Sci. Technol. 2016, 6, 1488–1495. [Google Scholar] [CrossRef]
  34. Singh, K.N.; Singh, P.; Kaur, A.; Singh, P. C-1 Alkynylation of N-methyltetrahydroisoquinolines through CDC: A direct access to phenethylisoquinoline alkaloids. Synlett 2012, 23, 760–764. [Google Scholar] [CrossRef]
  35. Voskressensky, L.G.; Titov, A.A.; Kobzev, M.S.; Samavati, R.; Borisov, R.S.; Kulikova, L.N.; Varlamov, A.V. The first synthesis of 6-(phenylethynyl)-substituted tetrahydroazocino[5, 4-b]indoles. Chem. Heteroc. Comp. 2016, 52, 68–70. [Google Scholar] [CrossRef]
  36. Voskressensky, L.G.; Borisova, T.N.; Kulikova, L.N.; Dolgova, E.G.; Kleimenov, A.I.; Sorokina, E.A.; Titov, A.A.; Varlamov, A.V. Reaction of 1-substituted tetrahydro-β-carbolines with activated alkynes-a new original approach to the synthesis of tetrahydroazocino[5, 4-b]indoles. Chem. Heteroc. Comp. 2007, 43, 587–598. [Google Scholar] [CrossRef]
  37. Voskressensky, L.G.; Borisova, T.N.; Ovcharov, M.V.; Kulikova, L.N.; Sorokina, E.A.; Borisov, R.S.; Varlamov, A.V. Transformations of tetrahydro-pyrido[4,3-d]pyrimidines[b]-condensed with isoxazole, thiazole, thiadiazole, and triazole units under the action of activated alkynes. Chem. Heteroc. Comp. 2008, 44, 1510–1519. [Google Scholar] [CrossRef]
  38. Voskressensky, L.G.; Kulikova, L.N.; Kleimenov, A.V.; Borisova, T.N.; Nikitina, E.V.; Listratova, A.V.; Varlamov, A.V. Interaction of 4-hydroxymethyl-2-(3, 4-dimethoxybenzyl)isoindoline with methyl propiolate. Chem. Heteroc. Comp. 2009, 45, 372–374. [Google Scholar] [CrossRef]
  39. Voskressensky, L.G.; Kulikova, L.N.; Gozun, S.V.; Khrustalev, V.N.; Borisova, T.N.; Listratova, A.V.; Ovcharov, M.V.; Varlamov, A.V. The reaction of tetrahydrochromeno[3,4-c]pyridines with activated alkynes. The first synthesis of tetrahydrochromeno[4, 3-d]azocines. Tetr. Lett. 2011, 52, 4189–4191. [Google Scholar] [CrossRef]
  40. Voskressensky, L.G.; Ovcharov, M.V.; Borisova, T.N.; Kulikova, L.N.; Listratova, A.V.; Borisov, R.S.; Varlamov, A.V. 2-Alkyl-4-oxohexahydropyrimido[4, 5-d]- and -[5, 4-d]azocines. Chem. Heteroc. Comp. 2011, 47, 222–228. [Google Scholar] [CrossRef]
  41. Voskressensky, L.G.; de Candia, M.; Carotti, A.; Borisova, T.N.; Kulikova, L.N.; Varlamov, A.V.; Altomare, C. Investigation on the antiplatelet activity of pyrrolo[3,2-c]pyridine-containing compounds. J. Pharm. Pharmacol. 2003, 55, 323–332. [Google Scholar] [CrossRef]
  42. Ciriaco, F.; Gambacorta, N.; Trisciuzzi, D.; Nicolotti, O. PLATO: A Predictive Drug Discovery Web Platform for Efficient Target Fishing and Bioactivity Profiling of Small Molecules. Int. J. Mol. Sci. 2022, 8, 5245. [Google Scholar] [CrossRef] [PubMed]
  43. Ciriaco, F.; Gambacorta, N.; Alberga, D.; Nicolotti, O. Quantitative polypharmacology profiling based on a multifingerprint similarity predictive approach. J. Chem. Inf. Model. 2021, 61, 4868–4876. [Google Scholar] [CrossRef] [PubMed]
  44. Montaruli, M.; Alberga, D.; Ciriaco, F.; Trisciuzzi, D.; Tondo, A.R.; Mangiatordi, G.F.; Nicolotti, O. Accelerating drug discovery by early protein drug target prediction based on multi-fingerprint similarity search. Molecules 2019, 24, 2233. [Google Scholar] [CrossRef] [PubMed]
  45. Purgatorio, R.; de Candia, M.; Catto, M.; Rullo, M.; Pisani, L.; Denora, N.; Carrieri, A.; Nevskaya, A.A.; Voskressensky, L.G.; Altomare, C.D. Evaluation of Water-Soluble Mannich Base Prodrugs of 2,3,4,5-Tetrahydroazepino[4,3-b]indol-1(6H)-one as Multitarget-Directed Agents for Alzheimer’s Disease. ChemMedChem 2021, 16, 589–598. [Google Scholar] [CrossRef]
  46. Landry, D.W.; Deng, S.; Arancio, O.; Fiorito, J.; Wasmuth, A. Phosphodiesterase Inhibitors and Uses Thereof. U.S. Patent 10,626,113 B2, 21 April 2020. [Google Scholar]
  47. Binde, C.D.; Tvete, I.F.; Gasemyr, J.; Natvig, B.; Klemp, M. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson’s disease. Br. J. Clin. Pharmacol. 2018, 84, 1917–1927. [Google Scholar] [CrossRef]
  48. Youdim, M.B.H. Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases. J. Neural. Transm. 2018, 125, 1719–1733. [Google Scholar] [CrossRef]
Molecules 28 01662 g001 550
Figure 1. Biologically active derivatives of benzo[b][1,6]naphthyridine.
Figure 1. Biologically active derivatives of benzo[b][1,6]naphthyridine.
Molecules 28 01662 g001
Molecules 28 01662 sch001 550
Scheme 1. Synthesis of 10-chloro-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridines.
Scheme 1. Synthesis of 10-chloro-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridines.
Molecules 28 01662 sch001
Molecules 28 01662 sch002 550
Scheme 2. The reaction of compounds 3a,b,d with activated alkynes.
Scheme 2. The reaction of compounds 3a,b,d with activated alkynes.
Molecules 28 01662 sch002
Molecules 28 01662 sch003 550
Scheme 3. Phenylethynylation of compounds 3a,c.
Scheme 3. Phenylethynylation of compounds 3a,c.
Molecules 28 01662 sch003
Molecules 28 01662 g002 550
Figure 2. Single crystal X-ray analysis of compound 5a (crystallographic data in Supplementary Materials).
Figure 2. Single crystal X-ray analysis of compound 5a (crystallographic data in Supplementary Materials).
Molecules 28 01662 g002
Molecules 28 01662 sch004 550
Scheme 4. The reaction of compound 5c,d,f,g with activated alkynes.
Scheme 4. The reaction of compound 5c,d,f,g with activated alkynes.
Molecules 28 01662 sch004
Molecules 28 01662 sch005 550
Scheme 5. Mechanism of interaction of 5c,d,f,g with activated alkynes.
Scheme 5. Mechanism of interaction of 5c,d,f,g with activated alkynes.
Molecules 28 01662 sch005
Molecules 28 01662 sch006 550
Scheme 6. Synthesis of 1-indol-3-yl derivatives of benzo[b][1,6]naphthyridines 8.
Scheme 6. Synthesis of 1-indol-3-yl derivatives of benzo[b][1,6]naphthyridines 8.
Molecules 28 01662 sch006
Molecules 28 01662 sch007 550
Scheme 7. Interaction of compound 8 with activated alkynes.
Scheme 7. Interaction of compound 8 with activated alkynes.
Molecules 28 01662 sch007
Table
Table 1. 1-R1-substituted-phenylethynyl derivatives 5a–h of compounds 3a,c with related synthesis yields.
Table 1. 1-R1-substituted-phenylethynyl derivatives 5a–h of compounds 3a,c with related synthesis yields.
Cmpd 5RR1Yield, %
aBnH24
bBn3-OMe35
cMeH32
dMe3-OMe85
eMe4-OMe88
fMe4-CF361
gMe4-F44
hMe4-Cl59
Table
Table 2. Compounds 6a–e with related reaction yields.
Table 2. Compounds 6a–e with related reaction yields.
Compound 6XR1Yield, %
aCO2Me4-F 27
bCO2Me3-OMe22
cCOMeH37
dCOMe3-OMe34
eCOMe4-CF342
Table
Table 3. Inhibitory activities of compounds 5c–h.
Table 3. Inhibitory activities of compounds 5c–h.
Cmpds 5MAO A
% Inhibition a		MAO B
% Inhibition aIC50 (μM) b
c24 ± 828 ± 1
d49 ± 2 7.09 ± 0.07
e24 ± 942 ± 6
f20 ± 1 14.3 ± 0.9
g39 ± 3 1.35 ± 0.07
h38 ± 4 8.65 ± 1.01
Pargyline10.9 ± 0.6 2.69 ± 0.48
a Inhibition (%) at 10 μM concentration. b Half-maximal inhibitory concentration (IC50, μM). Each value represents mean ± SD (n = 3).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kulikova, L.N.; Raesi, G.R.; Levickaya, D.D.; Purgatorio, R.; Spada, G.L.; Catto, M.; Altomare, C.D.; Voskressensky, L.G. Synthesis of Novel Benzo[b][1,6]naphthyridine Derivatives and Investigation of Their Potential as Scaffolds of MAO Inhibitors. Molecules 2023, 28, 1662. https://doi.org/10.3390/molecules28041662

AMA Style

Kulikova LN, Raesi GR, Levickaya DD, Purgatorio R, Spada GL, Catto M, Altomare CD, Voskressensky LG. Synthesis of Novel Benzo[b][1,6]naphthyridine Derivatives and Investigation of Their Potential as Scaffolds of MAO Inhibitors. Molecules. 2023; 28(4):1662. https://doi.org/10.3390/molecules28041662

Chicago/Turabian Style

Kulikova, Larisa N., Ghulam Reza Raesi, Daria D. Levickaya, Rosa Purgatorio, Gabriella La Spada, Marco Catto, Cosimo D. Altomare, and Leonid G. Voskressensky. 2023. "Synthesis of Novel Benzo[b][1,6]naphthyridine Derivatives and Investigation of Their Potential as Scaffolds of MAO Inhibitors" Molecules 28, no. 4: 1662. https://doi.org/10.3390/molecules28041662

APA Style

Kulikova, L. N., Raesi, G. R., Levickaya, D. D., Purgatorio, R., Spada, G. L., Catto, M., Altomare, C. D., & Voskressensky, L. G. (2023). Synthesis of Novel Benzo[b][1,6]naphthyridine Derivatives and Investigation of Their Potential as Scaffolds of MAO Inhibitors. Molecules, 28(4), 1662. https://doi.org/10.3390/molecules28041662

Article Metrics

Back to TopTop